Markets · News reference
Filed: 2026-07-24 AccNo: 0001104659-26-086651 Size: 234 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
Keep reading
Workday (NASDAQ:WDAY) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $2.61 by 5.36 percent. This is a 24.43 percent increase over earnings of $2.21 per share from the same
Read original at benzingaAutodesk (NASDAQ:ADSK) reported quarterly earnings of $3.30 per share which beat the analyst consensus estimate of $3.12 by 5.77 percent. This is a 25.95 percent increase over earnings of $2.62 per share from the same
Read original at benzingaAutodesk (NASDAQ:ADSK) is looking for Q3 GAAP EPS of $1.57-$1.87 vs $2.16 analyst estimate..
Read original at benzingaNutanix stock surged 9.87% after reporting Q4 2026 results that beat analyst expectations with $757.1 million in revenue (16% YoY growth) and $0.60 diluted EPS versus $0.49 expected. The company also generated strong free cash flow of $277.6 million and provided optimistic fiscal 2027 guidance of $3.18-$3.23 billion in revenue and $850-$950 million in free cash flow.
Read original at the-motley-foolSummit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-research